Concordia Pharmaceuticals Reports Encouraging Clinical Data in Patients with K-Ras Mutations Treated with First-in-Class Ras Antagonist, Salirasib

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Concordia Pharmaceuticals today reported encouraging new clinical data for salirasib, its novel small-molecule direct Ras antagonist, from two ongoing clinical trials – one in patients with advanced pancreatic cancer, and another in patients with advanced non-small cell lung cancer (NSCLC). The results in pancreatic cancer and NSCLC were reported in two abstracts (#4529 and 8012 respectively) released in advance of the American Society of Clinical Oncology 2009 Annual Meeting, and will be presented by investigators in two separate poster presentations.